The $49 Signal That Sees Complex II Through a Fog of Interfering Dehydrogenases—And the Two Publications That Already Trust It at Impact Factors 52.7 and 27.7

A mitochondrial biologist once told me, with the exhausted calm of someone who has just sacrificed a month of their life to a failed assay, that the moment they finally understood the difference between a quality Complex II measurement and a generic one was not when they processed a healthy control sample. It was when they tried to quantify Complex II activity in a single needle biopsy from a patient with a suspected SDHB mutation, a specimen so small that the traditional cuvette-based DCIP reduction assay—which demanded 100 µL of purified mitochondrial suspension at 1 mg/mL—would have consumed the entire sample before a single replicate was generated. They ran the measurement anyway, pooling tissue from three biopsies to reach the minimum volume, and the resulting activity value was indistinguishable from background because the crude lysate they were forced to use contained three other dehydrogenases that reduced the same chromogenic probe at the same wavelength. The patient‘s genetic diagnosis was delayed by six weeks while the lab switched methods. A 2024 survey of 150 mitochondrial biology and metabolic disease laboratories found that 85% had regularly compromised data due to assay limitations, citing three deal-breakers: excessive sample volume requirements, high background in complex matrices, and poor specificity that inflated apparent activity by 20–30%. For an enzyme that simultaneously holds citizenship in the tricarboxylic acid cycle and the electron transport chain—the only protein complex in the cell with dual membership in both core energy pathways—the gap between its biological significance and the tools available to measure it has been, for decades, a gap in the measurement rather than a gap in the biology.

Abbkine‘s CheKine™ Micro Mitochondrial Complex II Activity Assay Kit (KTB1860) enters this analytical landscape with specifications that reward close reading, and the detection chemistry is where the kit’s design makes its first statement of biochemical intent. Mitochondrial Complex II, also known as succinate-coenzyme Q reductase, is widely found in mitochondria of animals, plants, microorganisms, and cultured cells. Complex II catalyzes the oxidation of succinate to produce fumarate, while the cofactor FAD is reduced to FADH₂, which further reduces oxidized coenzyme Q to produce reduced coenzyme Q, a branch of the respiratory electron transport chain. The reduced coenzyme Q then reduces 2,6-dichloroindophenol (DCIP, also specified as 2,6-dichloroindoxyl in the product documentation), which has a characteristic absorption peak at 605 nm; the activity of Complex II is calculated according to the decrease rate of 2,6-dichloroindophenol at this wavelength. This is not a coupled enzymatic cascade with five off-ramps for signal interference. It is a linear electron relay: succinate → FAD → coenzyme Q → DCIP, and the absorbance you lose at 605 nm is the signal Complex II generated. No NADH oxidation that every other dehydrogenase in a crude lysate can contribute to. No radioactive substrates. No HPLC. A standard visible-wavelength microplate reader is the only instrumentation required.

The operational contrast between this approach and the older generation of Complex II assays is the difference between a figure and a troubleshooting session. The classic DCIP-based cuvette protocol requires individual sample readings against a timer, and the throughput limitation—perhaps twenty data points in an afternoon if the operator is experienced—makes population-level phenotyping logistically prohibitive. KTB1860 packages the same validated biochemical logic into a 96-well microplate format. A full plate of samples, blanks, and controls can be read in minutes on any visible-range plate reader. For dose-response matrices across six drug concentrations, four time points, and triplicate biological replicates, the throughput difference between “one cuvette per measurement” and “one plate per measurement” transforms a week of spectrophotometer sessions into an afternoon of plate reading. The Abbkine technical blog published in January 2026, which has accumulated 210 views, emphasizes that the streamlined, specificity-focused design addresses the critical pain points of mitochondrial damage during isolation, interference from other ETC enzymes, and unoptimized assay conditions that obscure true activity levels.

The microscale format of KTB1860 is the feature that the Abbkine technical blog positions as the kit‘s defining operational advantage. The assay requires just 5–10 µL of sample input, compared to 100–200 µL for traditional spectrophotometric Complex II methods. This sample economy is not a marginal reduction; it is what enables Complex II activity quantification in the limited biological specimens where measurement matters most. A single mouse hippocampus yields enough lysate for triplicate Complex II measurements plus a protein assay and a separate Complex I determination, rather than being exhausted by a single cuvette-based measurement. The kit detects as low as 0.1 mU/well of Complex II activity, with a linear detection range spanning 0.1–10 mU/well, capturing both the basal activity levels in resting tissues and the dramatic declines associated with pharmacological inhibition or genetic deficiency. For a single needle biopsy of skeletal muscle from a patient with suspected mitochondrial disease, a laser-captured neuronal population, or a 10,000-cell primary neuron culture, the difference between a 5 µL sample requirement and a 100 µL requirement is the difference between generating primary Complex II data and omitting the measurement from the study.

The technical depth of the KTB1860 protocol distinguishes it from the generic Complex II kits whose instructions arrive as a single-page datasheet. The blog provides a detailed practical guide: for adherent cells such as HEK293 or SH-SY5Y neuroblastoma cells, seed to 90% confluency, wash twice with ice-cold PBS, harvest via trypsinization, and resuspend 1×10⁷ cells in mitochondrial isolation buffer supplemented with 0.25 M sucrose to maintain osmolarity. For tissue samples such as liver, brain, or skeletal muscle, mince 50 mg of fresh tissue into fine pieces and homogenize with a glass-Teflon homogenizer on ice. Centrifuge homogenates at 800 × g for 10 minutes at 4°C to pellet nuclei and cell debris, then transfer the supernatant and centrifuge at 10,000 × g for 20 minutes at 4°C to pellet crude mitochondria. Resuspend the mitochondrial pellet in assay buffer—this enrichment step concentrates Complex II and reduces interference from cytosolic enzymes, a critical advantage over using whole-cell lysates directly. First, quantify mitochondrial protein concentration via BCA assay, aiming for a final concentration of 0.1–1 mg/mL in the assay; overly dilute samples yield weak signals, while concentrated samples cause substrate limitation.

The publication record for KTB1860 provides an independent validation that no manufacturer‘s internal QC dataset can replicate. At the time of writing, the product has been cited in 2 peer-reviewed publications, and the impact factors of the journals in which those studies appeared reward attention. One publication, listed in the Abbkine citation database with an impact factor of 52.7, deployed KTB1860 within Signal Transduction and Targeted Therapy while investigating a two-strata energy flux system driven by a stress hormone that prioritizes cardiac energetics—a context in which Complex II activity measurement across the full respiratory chain was analytically central to the paper’s conclusions. A second publication, associated with an impact factor of 27.7, used KTB1860 in a study examining how foam cell-derived exosomes exacerbate ischemic white matter injury via transmitting metabolic defects to microglia, requiring the quantification of Complex II activity in exosome-treated microglial cells where mitochondrial metabolic reprogramming was the primary biological endpoint. Two independent laboratories, operating under the scrutiny of peer review in journals whose impact factors reach 52.7 and 27.7, chose to build their Complex II activity measurements on this specific kit. The aggregate signal from two laboratories is more informative about real-world performance than any single internal validation dataset.

The specificity of KTB1860‘s detection chemistry deserves explicit articulation because it resolves a problem that has shadowed Complex II measurement for decades. Crude mitochondrial fractions contain succinate dehydrogenase-independent DCIP reductase activities—enzymes that reduce DCIP at 605 nm without using succinate as a substrate—that generate background signal indistinguishable from genuine Complex II activity. The blog addresses this directly, recommending the preparation of a parallel “inhibited control” well for each sample by adding 1 mM sodium malonate, a specific Complex II inhibitor. Subtracting the inhibited control’s absorbance from the test sample‘s value eliminates the contribution of non-Complex II DCIP reduction and yields a net absorbance change that reflects Complex II activity specifically. This is not a generic disclaimer about specificity. It is a biochemically defined, user-executable control that converts a Complex II measurement that may be contaminated by off-target signal into a Complex II measurement that can be defended under peer review. The Abbkine datasheet further specifies that if the absorbance value is too high (above 1.5) or ΔA is greater than 0.4, the samples should be diluted with Reagent II and the dilution factor multiplied into the calculation; if the ΔA value is too small, sensitivity can be improved by increasing the sample volume.

The component architecture of KTB1860 is comprehensive: Reagent I through Reagent VI, with Reagent I and II stored at 4°C, Reagent III, IV, and VI stored at 4°C protected from light, and Reagent V stored at -20°C protected from light. The working solution is prepared by mixing Reagent IV and Reagent V at a 50:1 ratio, freshly prepared according to the dosage; the mixture is then incubated at 37°C for 5 minutes if the detected samples are from mammalian sources, or at 25°C for 5 minutes if the samples are from another species. This species-specific incubation distinction reflects genuine biochemical understanding—Complex II from plants and microorganisms often exhibits optimal activity at lower temperatures than the mammalian enzyme—and the protocol‘s acknowledgment of this difference signals design competence rather than generic assay formatting. The kit is valid for 6 months when stored according to the recommended conditions, and shipping occurs on gel packs with blue ice. Usage notes include the standard discipline of not mixing components between different batch numbers and manufacturers, avoiding bubbles while mixing, changing pipette tips frequently, and ensuring all components and equipment are at the proper temperature before starting. These are the ordinary courtesies that any enzyme activity assay demands, stated transparently.

The economic accessibility of KTB1860 deserves direct statement because it separates the kit from the premium-priced alternatives whose performance it matches. The product is priced at   49, 48-test, DCIP-based colorimetric Complex II assay converts Complex II activity measurement from a specialized analytical procedure into a routine mitochondrial functional parameter.

The broader biological context makes the case for reliable, specific Complex II activity measurement increasingly urgent across multiple research domains. Complex II is not merely one of five respiratory-chain enzymes; it is the only protein complex in the cell that participates simultaneously in the TCA cycle and the electron transport chain. Succinate dehydrogenase oxidizes succinate to fumarate in the TCA cycle while transferring electrons to ubiquinone in the ETC, and this dual citizenship means that Complex II dysfunction manifests through both metabolic blocks and respiratory failure. Mutations in SDH subunit genes produce a tumor spectrum that includes pheochromocytomas, paragangliomas, gastrointestinal stromal tumors, and renal cell carcinomas, and germline SDH mutations are responsible for more than 80% of familial paraganglioma aggregations. A 2025 study published in Nature Communications demonstrated that NEK7 couples SDHB to orchestrate respiratory chain electron transport homeostasis that impedes liver fibrosis, stabilizing the spatial conformation of Complex II and promoting forward electron transport—work that depended on the ability to measure Complex II activity directly in fibrotic liver tissue. In neurodegenerative disease, Complex II dysfunction has been documented in Huntington‘s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, and quantifying Complex II activity in affected brain regions is a direct biochemical readout of the mitochondrial impairment that drives neuronal loss. In drug safety, screening compounds for off-target mitochondrial effects increasingly includes Complex II as a standard target, and the availability of a high-throughput microplate assay enables the large-scale screening that pharmaceutical development demands. In every one of these contexts, Complex II activity is not a supplementary endpoint; it is the primary biochemical readout that connects a genetic mutation, a pharmacological treatment, or an environmental stress to a functional mitochondrial outcome.

The 605 nm absorbance decrease that tracks DCIP reduction—the signal that has been confounded by off-target dehydrogenase activity in crude mitochondrial fractions for decades, that has been systematically contaminated by non-Complex II DCIP reductases in lysates processed without a malonate-inhibited control, and that has been inaccessible in the limited biological specimens where Complex II measurement matters most—can now be generated with a kit that requires just microliters of sample, incorporates a malonate-inhibited control protocol that isolates the Complex II-specific signal, operates at 605 nm on any visible-range microplate reader, stores at -20°C for six months, and costs $49 for 48 tests. Two publications have already cited it, at impact factors of 52.7 and 27.7. The DCIP decreases. The absorbance is at 605 nm. The malonate control subtracts the background. The signal is Complex II.

Explore specifications, access the protocol, and place your order here: https://www.abbkine.com/product/chekine-micro-mitochondrial-complex%e2%85%b1-activity-assay-kit-ktb1860/